| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| September 29th, 2005 | 34 | Yes |
Popular Name: Raloxifene hydrochloride Raloxifene hydrochloride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 82640-04-8 , 82640-04-8; 84449-90-1 , 84449-90-1 , [82640-04-8]
(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone
6-Hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl ketone, hydrochloride
82640-04-8; CPD000058508; Evista; SAM002548975
82640-04-8; D02217; Evista (TN); LY 156758; Raloxifene hydrochloride (JAN/USP)
82640-04-8; Prestwick_1035; Raloxifene hydrochloride
84449-90-1; C07228; LY 139481; Raloxifene
84449-90-1; D08465; Eviden (TN); Raloxifene (INN); Raxeto (TN)
CPD000058508; RALOXIFENE HYDROCHLORIDE; SAM002548975
Evista (Raloxifene Hydrochloride)
Evista, Raloxifene hydrochloride
LY-139481;RAL;Raloxifeno [Spanish];Raloxifenum [Latin]
Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-
Methanone, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-
Raloxifene Hydrochloride, keoxifene
raloxifene; raloxifeno; raloxifenum
[2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 6.22 | 10.88 | -44.71 | 3 | 5 | 1 | 71 | 474.602 | 7 | ↓ |
| Hi High (pH 8-9.5) | 6.22 | 8.67 | -11.05 | 2 | 5 | 0 | 70 | 473.594 | 7 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| MP | 266 - 268 | Enamine Building Blocks |
| MP | 266...268 | Enamine Building Blocks |
| ALOGPS_SOLUBILITY | 5.12e-04 g/l | DrugBank-approved |
| purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
| Purity | 95% | Fluorochem |
| Indications | anticancer, postmenopausal breast cancer and osteoporosis, hormone mimic | KeyOrganics Bioactives |
| Therapy | antiestrogen | SMDC Pharmakon |
| UniProt Database Links | AOXA_HUMAN; AOXA_RAT; AOXC_MOUSE; ESR1_HUMAN | ChEBI |
| Patent Database Links | EP0843999; EP0911321; EP0995748; EP1088550; EP1125582; EP1133996; EP1623712; EP1629835; EP1738759; EP1772150; EP1787642; EP1808163; EP1832576; EP1849480; EP1873258; EP1908463; EP1980246; EP1980255; EP1988098; US2001056096; US2002016368; US2002165255; US20 | ChEBI |
| Patent Database Links | EP0897721; EP0920862; EP0920863; EP1772150; EP1787642; US2006205757; US2007184075; US2007231410; WO2005003116; WO2006095185; WO2007109312; WO2007113268; WO2007113269; WO2007113270; WO2007128827; WO2007128829; WO2007135397; WO2007135411 | ChEBI |
| Target | Estrogen/progestogen Receptor | Selleck Chemicals |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Enamine; NCC_SUPPLIER_STRUCTURE_ID : 241392048; 1 hydrogen chloride | NIH Clinical Collection via PubChem |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Enamine; SUPPLIER_STRUCTURE_ID: 241392048; SALT: 1 hydrogen chloride | NIH Clinical Collection via PubChem |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| 5HT2B-4-E | Serotonin 2b (5-HT2b) Receptor (cluster #4 Of 4), Eukaryotic | Eukaryotes | 69 | 0.29 | Binding ≤ 10μM |
| EBP-1-E | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase (cluster #1 Of 1), Eukaryotic | Eukaryotes | 1 | 0.37 | Binding ≤ 10μM |
| ESR1-1-E | Estrogen Receptor Alpha (cluster #1 Of 5), Eukaryotic | Eukaryotes | 7 | 0.34 | Binding ≤ 10μM |
| ESR2-1-E | Estrogen Receptor Beta (cluster #1 Of 4), Eukaryotic | Eukaryotes | 8 | 0.33 | Binding ≤ 10μM |
| PLD1-1-E | Phospholipase D1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 8500 | 0.21 | Binding ≤ 10μM |
| PLD2-1-E | Phospholipase D2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3400 | 0.23 | Binding ≤ 10μM |
| SGMR1-1-E | Sigma Opioid Receptor (cluster #1 Of 6), Eukaryotic | Eukaryotes | 38 | 0.31 | Binding ≤ 10μM |
| ESR1-1-E | Estrogen Receptor Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 4 | 0.35 | Functional ≤ 10μM |
| ESR2-1-E | Estrogen Receptor Beta (cluster #1 Of 2), Eukaryotic | Eukaryotes | 7 | 0.34 | Functional ≤ 10μM |
| ADO-1-E | Aldehyde Oxidase (cluster #1 Of 3), Eukaryotic | Eukaryotes | 1100 | 0.25 | ADME/T ≤ 10μM |
| CP3A4-2-E | Cytochrome P450 3A4 (cluster #2 Of 4), Eukaryotic | Eukaryotes | 9900 | 0.21 | ADME/T ≤ 10μM |
| ERG2-2-F | C-8 Sterol Isomerase (cluster #2 Of 2), Fungal | Fungi | 66 | 0.30 | Binding ≤ 10μM |
| Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 3162 | 0.23 | Functional ≤ 10μM |
| Z50466-1-O | Trypanosoma Cruzi (cluster #1 Of 8), Other | Other | 10000 | 0.21 | Functional ≤ 10μM |
| Z50592-3-O | Oryctolagus Cuniculus (cluster #3 Of 8), Other | Other | 2000 | 0.23 | Functional ≤ 10μM |
| Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 5 | 0.34 | Functional ≤ 10μM |
| Z80561-1-O | U2OS (Osteosarcoma Cells) (cluster #1 Of 1), Other | Other | 3 | 0.35 | Functional ≤ 10μM |
| Z80936-1-O | HEK293 (Embryonic Kidney Fibroblasts) (cluster #1 Of 4), Other | Other | 4 | 0.35 | Functional ≤ 10μM |
| Z81068-1-O | Ishikawa (Uterine Carcinoma Cells) (cluster #1 Of 1), Other | Other | 23 | 0.31 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| EBP_HUMAN | Q15125 | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase, Human | 1 | 0.37 | Binding ≤ 1μM |
| ERG2_YEAST | P32352 | C-8 Sterol Isomerase, Yeast | 66 | 0.30 | Binding ≤ 1μM |
| ESR1_RAT | P06211 | Estrogen Receptor Alpha, Rat | 0.37 | 0.39 | Binding ≤ 1μM |
| ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 2 | 0.36 | Binding ≤ 1μM |
| ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 260 | 0.27 | Binding ≤ 1μM |
| ESR2_RAT | Q62986 | Estrogen Receptor Beta, Rat | 2.74 | 0.35 | Binding ≤ 1μM |
| 5HT2B_HUMAN | P41595 | Serotonin 2b (5-HT2b) Receptor, Human | 69 | 0.29 | Binding ≤ 1μM |
| SGMR1_HUMAN | Q99720 | Sigma Opioid Receptor, Human | 38 | 0.31 | Binding ≤ 1μM |
| EBP_HUMAN | Q15125 | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase, Human | 1 | 0.37 | Binding ≤ 10μM |
| ERG2_YEAST | P32352 | C-8 Sterol Isomerase, Yeast | 66 | 0.30 | Binding ≤ 10μM |
| ESR1_RAT | P06211 | Estrogen Receptor Alpha, Rat | 0.37 | 0.39 | Binding ≤ 10μM |
| ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 2 | 0.36 | Binding ≤ 10μM |
| ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 260 | 0.27 | Binding ≤ 10μM |
| ESR2_RAT | Q62986 | Estrogen Receptor Beta, Rat | 2.74 | 0.35 | Binding ≤ 10μM |
| PLD1_HUMAN | Q13393 | Phospholipase D1, Human | 4000 | 0.22 | Binding ≤ 10μM |
| PLD2_HUMAN | O14939 | Phospholipase D2, Human | 10000 | 0.21 | Binding ≤ 10μM |
| 5HT2B_HUMAN | P41595 | Serotonin 2b (5-HT2b) Receptor, Human | 69 | 0.29 | Binding ≤ 10μM |
| SGMR1_HUMAN | Q99720 | Sigma Opioid Receptor, Human | 38 | 0.31 | Binding ≤ 10μM |
| ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 0.37 | 0.39 | Functional ≤ 10μM |
| ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 0.37 | 0.39 | Functional ≤ 10μM |
| Z80936 | Z80936 | HEK293 (Embryonic Kidney Fibroblasts) | 4 | 0.35 | Functional ≤ 10μM |
| Z81068 | Z81068 | Ishikawa (Uterine Carcinoma Cells) | 4.32 | 0.34 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 0.1 | 0.41 | Functional ≤ 10μM |
| Z50592 | Z50592 | Oryctolagus Cuniculus | 2000 | 0.23 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 2511.88643 | 0.23 | Functional ≤ 10μM |
| Z50466 | Z50466 | Trypanosoma Cruzi | 10000 | 0.21 | Functional ≤ 10μM |
| Z80561 | Z80561 | U2OS (Osteosarcoma Cells) | 3.1 | 0.35 | Functional ≤ 10μM |
| ADO_HUMAN | Q06278 | Aldehyde Oxidase, Human | 0.9 | 0.37 | ADME/T ≤ 10μM |
| ADO_MOUSE | O54754 | Aldehyde Oxidase, Mouse | 500 | 0.26 | ADME/T ≤ 10μM |
| ADO_RAT | Q9Z0U5 | Aldehyde Oxidase, Rat | 1100 | 0.25 | ADME/T ≤ 10μM |
| ADO_MACFA | Q5FB27 | Aldehyde Oxidase, Macfa | 500 | 0.26 | ADME/T ≤ 10μM |
| CP3A4_HUMAN | P08684 | Cytochrome P450 3A4, Human | 9900 | 0.21 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Aflatoxin activation and detoxification | |
| Cholesterol biosynthesis | |
| G alpha (q) signalling events | |
| Nuclear Receptor transcription pathway | |
| Nuclear signaling by ERBB4 | |
| Role of phospholipids in phagocytosis | |
| Serotonin receptors | |
| Synthesis of PA | |
| Synthesis of PG | |
| Vitamins B6 activation to pyridoxal phosphate | |
| Xenobiotics |
